WO2006003094A2 - Merocyanine derivatives - Google Patents

Merocyanine derivatives Download PDF

Info

Publication number
WO2006003094A2
WO2006003094A2 PCT/EP2005/052850 EP2005052850W WO2006003094A2 WO 2006003094 A2 WO2006003094 A2 WO 2006003094A2 EP 2005052850 W EP2005052850 W EP 2005052850W WO 2006003094 A2 WO2006003094 A2 WO 2006003094A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
hydrogen
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/052850
Other languages
English (en)
French (fr)
Other versions
WO2006003094A3 (en
Inventor
Barbara Wagner
Frank Bienewald
Heinz Wolleb
Olof Wallquist
Bernd Herzog
Thomas Ehlis
Jürg Haase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Ciba SC Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Spezialitaetenchemie Holding AG, Ciba SC Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Priority to JP2007518585A priority Critical patent/JP5078611B2/ja
Priority to US11/630,489 priority patent/US7772242B2/en
Priority to EP05756874A priority patent/EP1761237A2/en
Priority to CN200580029199.XA priority patent/CN101010063B/zh
Priority to BRPI0512730A priority patent/BRPI0512730B1/pt
Publication of WO2006003094A2 publication Critical patent/WO2006003094A2/en
Publication of WO2006003094A3 publication Critical patent/WO2006003094A3/en
Anticipated expiration legal-status Critical
Priority to US12/715,839 priority patent/US8044058B2/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to the use of the compounds of formula
  • R 1 is hydrogen; C 2 -Ci 2 alkenyl; C 2 -Ci 2 alkinyl;
  • R 4 is cyano; COR 7 , COOR 7 ; CONR 7 R 8 ; SO 2 (C 6 -C 12 )aryl; C 2 -C 12 alk-1-enyl; C 3 -Ci 2 cycloalk-1- enyl; C 2 -Ci 2 alk-1-inyl; C ⁇ -C ⁇ heteroalkyl; C 3 -C 5 heterocycloalkyl; C 6 -Ci 0 aryl; or d-
  • R 5 is -COR 7 ; -COOR 7 ; -OR 7 ; -SR 7 , -NHR 7 , -NR 7 R 8 ; d-C ⁇ alkyl; C 2 -Ci 2 alkenyl; C 2 -C 12 alkinyl;
  • Ci 2 heteroalkyl drCnheteroaralkyl; C 6 -Ci 0 aryl; Ci-Cgheteroaryl; Si-Ri 0 RnRi 2 ;
  • SiI is a silane-, oligosiloxane- or polysiloxane radical; R 1 and R 2 , Ri and Q 1 Ri and R 6 , Ri and T, R 2 and R 3 , R 2 and R 4 , R 2 and R 6 , R 2 and Q, R 4 and R 6 , R 4 and T, R 6 and Q, T and Q, each independently, are linked together, so that 1,
  • 2, 3 or 4 carbocyclic or N, O and/or S-heterocyclic rings are formed, wherein each of them, independently from each other, may be condensed with an aromatic or heteroaromatic ring, and/or more N-, O- and/or S-heterocycIic rings, and each N atom in a N-heterocyclic ring may be substituted by d-C&alkyl;
  • T is -COR 5 ; -CN; C 6 -Ci 0 aryl; -NHR 5 ; or -SO 2 -(C 6 -C 12 )aryl; R 2 and R 3 independently from each other are d-C ⁇ alkyl; hydroxy-d-C ⁇ alkyl; C 2 -C 12 alkenyl;
  • T is a bivalent radical of formula -NR 7 -V-NR 7 -, wherin
  • V is phenylene; or Ci-C 5 alkylene;
  • Alkyl, cycloalkyl, alkenyl, alkylidene or cycloalkenyl may be straight chained or branched, monocyclic or polycyclic.
  • Alkyl ist for example methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert.-butyl, n-penlyl, 2-pentyl, 3-pentyl, 2,2-dimethyl propyl, n-hexyl, n-octyl, 1,1,3,3-tetramethylbutyl, 2-ethyIhexyl, nonyl, decyl, n-octadecyl, eicosyl or dodecyl.
  • Alkenyl is for example straight-chain C 2 -C 12 alkenyl or preferably branched C 3 -C 12 alkenyl.
  • Ci-C 12 alkyl like vinyl, allyl, 2-propen-2-yl, 2-buten-1-yl, 3-buten-1-yl, 1,3-butadien-2-yl, 2-cy- clobuten-1-yl, 2-penten-1-yl, 3-penten-2-yl, 2-methyl-1-buten-3-yl, 2-methyl-3-buten-2-yl, 3-methyl-2-buten-1-yl, 1 ,4-pentadien-3-yl, 2-cyclopenten-1-yl, 2-cyclohexen-1-yl, 3-cyclo- hexen-1-yl, 2,4-cyclohexadien-i-yl, 1-p-menthen- ⁇ -yl, 4(10)-thujen-10-yl, 2-norbornen-1-yl, 2,5-nor
  • C 3 -C 12 cycloalkyl is for example cyclopropyl, cyclobutyl, cyclopentyl, trimethylcyclohexyl or preferably cyclohexyl.
  • C 7 -C 18 aralkyl is for example benzyl, 2-benzyl-2-propyl, ⁇ -phenyl-ethyl, 9-fluorenyl, ⁇ , ⁇ -di- methylbenzyl, co-phenyl-butyl, ⁇ -phenyl-octyl, ⁇ >-phenyl-dodecyl oder 3-methyl-5-(1',1',3',3'- tetramethyl-butyl)-benzyl.
  • (CrC 6 )alkylidene is for example methylene, ethyl-1-ene, propyl-2-ene.
  • C 6 -C 14 ayrl is for example phenyl, naphthyl, biphenylyl, 2-fluorenyl, phenanthryl, anthracenyl or terphenylyl.
  • Ci-Ci 2 heteroaryl is an unsaturated or aromatic radical having 4n+2 conjugated ⁇ -electrons, for example 2-thienyl, 2-furyl, 2-pyridyl, 2-thiazolyl, 2-oxazolyl, 2-imidazolyl, isothiazolyl, tri- azolyl, tetrazolyl or another ring system from thiophene-, furan-, pyridine, thiazol, oxazol, imi- dazol, isothiazol, triazol, pyridine- and benzene rings, which are unsubstituted or substituted by 1 to 6 ethyl, methyl, ethylene and/or methylene, like benzotriazolyl, bei N-heterocycles optionally in the form of their N-oxides.
  • C 2 -Ci 6 heteroaralkyl is for example C r C 8 alkyl substituted with CrC 8 heteroaryl.
  • R 1 is hydrogen; -OR 7 , -SR 7 ; -NR 7 R 8 ; CrC ⁇ alkyl; C 2 -Ci 2 alkenyl; C 2 -Ci 2 alkinyl; C 3 -
  • R 4 is cyano; COR 7 , COOR 7 ; CONR 7 R 8 ; SO 2 (C 6 -C 12 )aryl, C 2 -C 12 alk-1-enyl; C 3 -C 12 cycloalk-1- enyl; C 2 -C 12 BIk-I -inyl;, C 2 -C 12 heteroalkyl, C 3 -C 5 heterocycloalkyl, Ce-doaryl; Or C 1 -
  • R 5 is -COR 7 ; -COOR 7 ; -OR 7 ; -SR 7 ; -NR 7 R 8 ; CrC ⁇ alkyl; C 2 -C 12 alkenyl; C 2 -C 12 alkinyl; C 3 -
  • R 6 is d-C ⁇ alkyl; d-C ⁇ alkoxy; or COR 7 ; R 7 and R 8 independently from each other are hydrogen; CrC ⁇ alkyl; C 2 -C 12 alkenyl; C 2 -
  • R 9 is a (CrC 6 )alkylidene radical; or R 1 and R 2 , R 1 and Q, R 1 and R 4 , R 1 and R 6 , R 2 and R 3 , R 3 and Q 1 R 6 and Q, T and Q, each independently, are linked together, so that 1, 2, 3 or 4 carbocyclic or N, O and/or S- heterocyclic rings are formed, wherein each of them, independently from each other, may be condensed with an aromatic or heteroaromatic ring, and/or more N-, O- and/or
  • S-heterocycic rings and each N atom in a N-heterocyclic ring may be substituted by d-C ⁇ alkyl; and n is 1.
  • Q is -OH; -OR 6 ; or -NR 7 R 8 ;
  • T is -COR 5 -CN; or -SO 2 -(C 6 -C 12 )aryl;
  • R 1 is hydrogen; -OR 7 , -SR 7 ; -NR 7 R 8 ; C 1 -C 22 BIlCyI; C 2 -Ci 2 alkenyl; C 2 -C 12 alkinyl; C 3 -
  • Ci 2 cycloalkyl C 3 -C 12 cycloalkenyl; C 7 -C 12 aralkyl; or C 6 -C 10 aryl;
  • R 4 is cyano; -COR 5 , -COOR 7 ; -CONR 7 R 8 ; -SO 2 (C 6 -Ci 2 )aryl; -C 1 -C 22 Sl kylcarbonylamino-C 6 - Cioaryl; or C 6 -Ci 0 aryl;
  • R 5 is -COR 7 ; -COOR 7 ; -CONR 7 R 8 , -OR 7 , -SR 7] -NR 7 R 8 , d-C ⁇ alkyl; C 2 -C 12 alkenyl; C 2 -Ci 2 alkinyl; C 3 -C 12 cycloalkyl; C 3 -Ci 2 cycloalkenyl; C 7 -Ci 2 aralkyl; C 6 -Ci 0 aryl; or C 1 - Ci 2 alkoxy-C 6 -Ci 0 aryl;
  • R 6 , R 7 and R 8 independently from each other are hydrogen; d-Q ⁇ alkyl; C 3 -Ci 2 cycloalkyl; C 3 -C 12 cycloalkenyl; C 7 -C 12 aralkyl; or C 6 -Ci O aryl; or
  • Ri and R 2 , Ri and Q, Ri and R 4 , Ri and R 6 , R 2 and R 3 , R 3 and Q 1 R 6 and Q, T and Q are linked together pairwise, so that 1, 2, 3 or 4 carbocyclic or N-, O- and/or S-heterocyclic rings are formed, wherein each of them, independently from each other may be con ⁇ densed with an aromatic or heteroaromatic ring, and/or more N, O and/or S-heterocycic rings, and each N atom in a N-heterocyclic ring may be substituted by CrC 22 alkyl.
  • R 1 is hydrogen; -S-d-C ⁇ alkyl; or Ri and R 2 , or R 1 and R 4 together with the linking nitrogen atom form an alkylene radical which my be interrupted by one or more -O- and/or -NR 7 - or may be condensed with an aromatic ring; and R 7 is d-C ⁇ alkyl; C 3 -Ci 2 cycloalkyl; C 3 -C 12 cycloalkenyl; C 7 -Ci 2 aralkyl; or C 6 -C 10 aryl.
  • R 2 and R 3 independently from each other are C r C 5 alkyl; phenyl-CrC 3 alkyl; hydroxy-d-
  • Ci 2 alkyl; or R 2 and R 3 , or R 2 and R 4 , or R 2 and Q together with the linking nitrogen atom form an alkylene radical which my be interrupted by one or more -O- and/or -NR 7 - or may be condensed with an aromatic ring; and
  • R 7 is d-C ⁇ alkyl; C 3 -C 12 cycloalkyl; C 3 -C 12 cycloalkenyl; C 7 -C 12 aralkyl; or C 6 -C 10 aryl; And most preferably the use of the compounds of formula (1), wherein R 2 and R 3 independently from each other are d-C 5 alkyl; or R 2 and R 3 together with the linking nitrogen atom form a C 2 -dalkylene radical which may be interrupted by -O- or
  • R 4 is -COR5; phenyl, which is optionally substituted by Ci-Csalkyl; -CN; or -SO 2 -(C6-Ci 0 )aryl; or R 4 and T together with a bivalent C3-C 7 alkylene radical which my be interrupted by one or more -O- and/or -NR 7 - form a carbocyclic ring which may be condensed with an aromatic ring; and R 7 is hydrogen; or C r C 5 alkyl.
  • R 4 is -CN; or COR 6 ;
  • R 5 is Ci-Ci 2 alkyl; or d-Ci 2 alkoxy; or
  • U 1 and U 3 independently from each other are a radical of formula -CHR 7 ; -NHR 7 -; or -O-;
  • U 2 is -CH 2 ; or -CO-; or the direct bond;
  • R 7 is hydrogen; or CrCi 2 alkyl; form an aromatic ring.
  • R 6 is hydrogen; Ci-C 5 alkyl; C r C 5 alkoxy; -O-(C 6 -C 10 aryl); or R 6 and Q together with a bivalent C 3 -C 7 alkylene radical which may be interrupted by one or more -O- and/or -NR 7 - or may be condensed with an aromatic ring, form a heterocyclic ring; and
  • R 7 is hydrogen; or CiC 12 alkyl; and most preferably wherein
  • R 6 is hydrogen
  • T is -CN; -COR 5 ; or -SO 2 -phenyl;
  • R 5 is Ci-C 5 alkyl; d-C 5 alkoxy; or NR 7 R 8 ;
  • R 7 and Re independently from each other are hydrogen; or C r C 5 alkyl; or
  • T and Q together with the bivalent C 3 -C 7 alkylene radical which may be interrupted by one or more -O- and/or -NR 7 - or may be condensed with an aromatic ring, form a heterocyclic ring; and most preferably the use of compounds of formula (1), wherein
  • T is -CN; or -COR 5 ;
  • R 5 is Ci-C 5 alkyl; or C r C 5 alkoxy.
  • Q is hydroxy; CrC 5 alkoxy; or -NR 7 Rs;
  • R 7 and R 8 independently from each other are hydrogen; CrC 5 alkyl; or phenyl, which may be substituted by one or more Ci-C 5 alkyl or d-C 3 alkoxy groups; and most preferably, wherein Q is hydroxy.
  • U 4 , U 5 , U 6 , U 7 and U 8 independently of each other are -CHR 5 -; -CO-; -NR 7 -; -CS-; or-O-;
  • R 5 is hydrogen; or C r C 5 alkyl
  • Ri ⁇ R2, R3. R ⁇ i R7 and Q are defined as in formula (1).
  • R 5 is hydrogen; or Ci-C 5 alkyl
  • R 3 , R 4 , and T are defined as in formula (1); more preferably, wherein
  • R 3 is C r C 22 alkyl; C 6 -C 10 aryl; or C 7 -Ci 2 aralkyl; and most preferably, wherein
  • Q is hydrogen; or d-Qgalkyl
  • T is -COR 5 ; -CN; or -SO 2 -(C 6 -C 12 )aryl;
  • Ri is hydrogen; or d-Q ⁇ alkyl
  • R 2 and R 3 independently from each other are d-C ⁇ alkyl
  • R 4 is CN; COR 5 ; CONH 2 ; or SO 2 (C 6 -Ci 2 )aryl,
  • R 5 is -OR 7 ; -SR 7 , -NHR 7 , -NR 7 R 8 ; d-C ⁇ alkyl; C 7 -C 12 aralkyl;
  • R 7 and R 8 independently from each other are hydrogen; d-C ⁇ alkyl; -(CH 2 ) m -Si-Ri 0 RnRi 2 ; Si(OR 10 )(OR 11 )(OR 12 ); SiR 10 (OR 11 )(OR 12 ); SiR 10 R 11 (OR 12 ), or a radical X-SiI;
  • R 9 is a (Ci-C 6 )alkylidene radical
  • R-io, R- 11 , Ri 2 independently form each other are d-C ⁇ alkyl
  • X is a linker
  • SiI is a silane-, oligosiloxane- or polysiloxane radical
  • R 1 and R 2 , R 1 and Q, R 1 and R 6 , R 1 and T, R 2 and R 3 , R 2 and R 4 , R 2 and R 6 , R 2 and Q, R 4 and R 6 , R 4 and T, R 6 and Q, T and Q, each independently, are linked together, so that 1 , 2, 3 or 4 carbocyclic or N, O and/or S-heterocyclic rings are formed, wherein each of them, independently from each other, may be condensed with an aromatic or heteroaromatic ring, and/or more N-, O- and/or S-heterocycic rings, and each N atom in a N-heterocyclic ring may be substituted by d-C ⁇ alkyl; n is anumber from 1 to 4; and m is a number for O to 4; wherein at least one of the radicals R 1 , R 6 or Q is different from hydrogen; Preferred is the usse of compounds of formula (1), wherein
  • Ri, R 6 and Q independently from each other are hydrogen; or d-C ⁇ alkyl, wherein at least one of Ri 1 R 6 and Q is different from hydrogen; and most preferrd the use of compounds of formula (1), wherein
  • Ri, R 6 and Q independently from each other are hydrogen; or CrC 5 alkyl, wherein at least one of Ri, R 6 and Q is different from hydrogen.
  • T and R 4 independently from each other are -COR 5 ; -CN; or -S ⁇ 2 -(C 6 -Ci 2 )aryl; and
  • R 5 is -OR 7 ; -NR 7 R 8 ; CrC ⁇ alkyl; C 7 -Ci 2 aralkyl;
  • R 7 and R 8 independently from each other are hydrogen; d-C ⁇ alkyl; -(CH 2 ) m -Si-RioRiiRi 2 ; and R10.
  • Rii. and R12 independently from each other are Ci-C2 2 alkyl.
  • T and R 4 independently from each other are -CN; SO 2 C 6 H 5 ; -c— ⁇ ; or a radical of
  • R 7 and Rs independently from each other are CrCi 2 alkyl; or a radical of formula
  • R 1 0, R11 and Ri 2 are CrC 5 alkyl.
  • R 1 , R 2 , R 4 and R 6 are defined as in formula (1).
  • the compounds of formula (1) are prepared according to known processes, as disclosed for example in J.Org.Chem. USSR (Engl.TransL) 26(8), p. 1562f (1990); J.Heterocycl.Chem. 33(3). p. 763-766 (1996); Khimiya Geterotsiklicheskikh Soedinenii H, p. 1537-1543 (1984); Khimiya Geterotsiklicheskikh Soedinenii 3, p. 397-404 (1982); Chem.Heterocycl.Comp. (Engl.Trans ⁇ 24(8). 914-919 (1988).
  • Vinylogene CH-acid compounds are reacted with acetales of amides.
  • the compounds of the formula (1 ) according to the present invention are particularly suitable as UV filters, i.e. for protecting ultraviolet-sensitive organic materials, in particular the skin and hair of humans and animals, from the harmful effects of UV radiation. These compounds are therefore suitable as sunscreens in cosmetic, pharmaceutical and veterinary medical preparations. These compounds can be used both in dissolved form and in the micronized state.
  • the UV absorbers according to the present invention can be used either in the dissolved state (soluble organic filters, solubelized organic filters) or in the micronised state (nano- scalar organic filters, particulate organic filters, UV-absorber pigments).
  • any known process suitable for the preparation of microparticles can be used for the pre ⁇ paration of the micronised UV absorbers, for example wet-milling,wet-kneading, spray- drying from a suitable solvent, by the expansion according to the RESS process (Rapid Expansion of Supercritical Solutions) by reprecipitation from suitable solvents.
  • RESS process Rapid Expansion of Supercritical Solutions
  • the micronised UV absorbers so obtained usually have an average particle size from 0.02 to 2, preferably from 0.03 to 1.5, and more especially from 0.05 to 1.0 micrometer.
  • a further object of the present invention is a UV absorber dispersion, comprising
  • the cosmetic formulations or pharmaceutical compositions according to the present inven ⁇ tion may additionally contain one or more than one further conventional UV filter.
  • the cosmetic or pharmaceutical preparations may be, for example, creams, gels, lotions, al ⁇ coholic and aqueous/alcoholic solutions, emulsions, wax/fat compositions, stick preparations, powders or ointments.
  • the cosmetic or pharma ⁇ ceutical preparations may contain further adjuvants as described below.
  • the preparations contain, for example, from 0.1 to 30 % by weight, preferably from 0.1 to 15 % by weight and especially from 0.5 to 10 % by weight, based on the total weight of the composition, of one or more UV absorbers, from 1 to 60 % by weight, espec ⁇ ially from 5 to 50 % by weight and preferably from 10 to 35 % by weight, based on the total weight of the composition, of at least one oil component, from 0 to 30 % by weight, especially from 1 to 30 % by weight und preferably from 4 to 20 % by weight, based on the total weight of the composition, of at least one emulsifier, from 10 to 90 % by weight, especially from 30 to 90 % by weight, based on the total weight of the composition, of water, and from 0 to 88.
  • UV absorbers from 1 to 60 % by weight, espec ⁇ ially from 5 to 50 % by weight and preferably from 10 to 35 % by weight, based on the total weight of the composition,
  • the compounds of formula (1) may also be used as as an anti-wrinkle perception modifier (see Example 29). This is a futher object of the present invention.
  • UV absorbers are of special interest:
  • the cosmetic or pharmaceutical preparations may be, for example, creams, gels, lotions, alcoholic and aqueous/alcoholic solutions, emulsions, wax/fat compositions, stick prepa ⁇ rations, powders or ointments.
  • the cosmetic or pharmaceutical preparations may contain further adjuvants as described below.
  • the preparations contain, for example, from 0.1 to 30 % by weight, pre ⁇ ferably from 0.1 to 15 % by weight and especially from 0.5 to 10 % by weight, based on the total weight of the composition, of one or more UV absorbers, from 1 to 60 % by weight, especially from 5 to 50 % by weight and preferably from 10 to 35 % by weight, based on the total weight of the composition, of at least one oil component, from 0 to 30 % by weight, especially from 1 to 30 % by weight und preferably from 4 to 20 % by weight, based on the total weight of the composition, of at least one emulsifier, from 10 to 90 % by weight, especially from 30 to 90 % by weight, based on the total weight of the composition, of water, and from 0 to 88.9 % by weight, especially
  • the cosmetic or pharmaceutical compositions/preparations according to the invention may also contain one or one more additional compoundsl like fatly alcohols, esters of fatty acids, natural or synthetic triglycerides including glyceryl esters and derivatives, pearlescent waxes:hydrocarbon oils: silicones or siloxanes (organosubstituted super-fatting agents, surfactantsconsistency regulators/thickeners and rheology modifiers, polymers, biogenic active ingredients, deodorising active ingredients, anti-dandruff agents, antioxidants, hydrotropic agents, preservatives and bacteria-inhibiting agents, perfume oils, colourants, polymeric beads or hollow spheres as spf enhancers,
  • Cosmetic or pharmaceutical formulations are contained in a wide variety of cosmetic preparations. There come into consideration, for example, especially the following preparations:
  • skin-care preparations e.g. skin-washing and cleansing preparations in the form of tablet-form or liquid soaps, soapless detergents or washing pastes, bath preparations, e.g. liquid. (foam baths, milks, shower preparations) or solid bath preparations, e.g. bath cubes and bath salts; skin-care preparations, e.g. skin emulsions, multi-emulsions or skin oils; cosmetic personal care preparations, e.g. facial make-up in the form of day creams or powder creams, face powder (loose or pressed), rouge or cream make-up, eye-care preparations, e.g.
  • eyeshadow preparations mascara, eyeliner, eye creams or eye-fix creams
  • lip-care preparations e.g. lipsticks, lip gloss, lip contour pencils, nail-care preparations, such as nail varnish, nail varnish removers, nail hardeners or cuticle removers
  • foot-care preparations e.g. foot baths, foot powders, foot creams or foot balsams, special deodorants and antiperspirants or callus-removing preparations
  • light-protective preparations such as sun milks, lotions, creams or oils, sunblocks or tropicals, pre-tanning preparations or after-sun preparations
  • skin-tanning preparations e.g.
  • depigmenting preparations e.g. preparations for bleaching the skin or skin-lightening preparations
  • insect-repellents e.g. insect-repellent oils, lotions, sprays or sticks
  • deodorants such as deodorant sprays, pump-action sprays, deodorant gels, sticks or roll-ons
  • antiperspirants e.g. antiperspirant sticks, creams or roll-ons
  • preparations for cleansing and caring for blemished skin e.g. synthetic detergents (solid or liquid), peeling or scrub preparations or peeling masks
  • hair-removal preparations in chemical form (depilation) e.g.
  • hair-removing powders liquid hair-removing preparations, cream- or paste-form hair-removing preparations, hair- removing preparations in gel form or aerosol foams
  • shaving preparations e.g. shaving soap, foaming shaving creams, non-foaming shaving creams, foams and gels, preshave preparations for dry shaving, aftershaves or aftershave lotions
  • fragrance preparations e.g. fragrances (eau de Cologne, eau de toilette, eau de perfume, perfume de toilette, perfume), perfume oils or perfume creams
  • cosmetic hair-treatment preparations e.g. hair-washing preparations in the form of shampoos and conditioners, hair-care preparations, e.g.
  • pretreatment preparations hair tonics, styling creams, styling gels, pomades, hair rinses, treatment packs, intensive hair treatments, hair-sthjcturing preparations, e.g. hair-waving preparations for permanent waves (hot wave, mild wave, cold wave), hair-straightening preparations, liquid hair- setting preparations, hair foams, hairsprays, bleaching preparations, e.g. hydrogen per ⁇ oxide solutions, lightening shampoos, bleaching creams, bleaching powders, bleaching pastes or oils, temporary, semi-permanent or permanent hair colourants, preparations containing self-oxidising dyes, or natural hair colourants, such as henna or camomile.
  • hair-waving preparations for permanent waves hot wave, mild wave, cold wave
  • hair-straightening preparations liquid hair- setting preparations
  • hair foams hairsprays
  • bleaching preparations e.g. hydrogen per ⁇ oxide solutions, lightening shampoos, bleaching creams, bleaching powders, bleach
  • liquid preparations as a W/O, OfSN, OfSNIO, W/O/W or PIT emulsion and all kinds of microemulsions, in the form of a gel, in the form of an oil, a cream, milk or lotion, in the form of a powder, a lacquer, a tablet or make-up, in the form of a stick, in the form of a spray (spray with propellent gas or pump-action spray) or an aerosol, in the form of a foam, or in the form of a paste.
  • a spray spray with propellent gas or pump-action spray
  • aerosol in the form of a foam, or in the form of a paste.
  • cosmetic preparations for the skin are light-protective preparations, such as sun milks, lotions, creams, oils, sunblocks or tropicals, pretanning preparations or after-sun preparations, also skin-tanning preparations, for example self-tanning creams.
  • light-protective preparations such as sun milks, lotions, creams, oils, sunblocks or tropicals
  • pretanning preparations or after-sun preparations also skin-tanning preparations, for example self-tanning creams.
  • sun protection creams, sun protection lotions, sun protection milk and sun protection preparations in the form of a spray are particularly interested.
  • hair-washing preparations in the form of shampoos, hair conditioners, hair-care preparations, e.g. pretreatment preparations, hair tonics, styling creams, styling gels, pomades, hair rinses, treatment packs, intensive hair treatments, hair- straightening preparations, liquid hair-setting preparations, hair foams and hairsprays.
  • hair-washing preparations in the form of shampoos.
  • a shampoo has, for example, the following composition: from 0.01 to 5 % by weight of a UV absorber according to the invention, 12.0 % by weight of sodium laureth-2-sulfate, 4.0 % by weight of cocamidopropyl betaine, 3.0 % by weight of sodium chloride, and water ad 100%.
  • compositions are preservatives, bactericides and bacterio ⁇ static agents, perfumes, dyes, pigments, thickening agents, moisturizing agents, humectants, fats, oils, waxes or other typical ingredients of cosmetic and personal care formulations such as alcohols, poly-alcohols, polymers, electrolytes, organic solvents, silicon derivatives, emollients, emulsifiers or emulsifying surfactants, surfactants, dispersing agents, antioxi ⁇ dants, anti-irritants and anti-inflammatory agents etc.
  • the cosmetic preparation according to the invention is distinguished by excellent protection of human skin against the damaging effect of sunlight.
  • the reactio mixture is sitrred for 4 h at 3°C and finally for 16 h at room temperture.
  • the raw product is filtered off and washed with diethylether and finally 4 times with 10 ml methanol.
  • Part A and part B are heated separately to 75°C.
  • Part A is poured into part B under con ⁇ tinuous stirring.
  • Cyclopentasiloxane and PEG-12 Di ⁇ methicone from part D are incorporated into the mixture.
  • the mixture is homo ⁇ genized with an Ultra Turrax at 11 000 rpm for 30 sec.
  • After cooling down to 65°C Sodium Acrylates Copolymer (and) Paraffinium Liquidum (and) PPG-1 Trideceth-6 are incorporated.
  • Part C is added at a temperature ⁇ 5O 0 C.
  • Tocopheryl Acetate is incorporated and subsequently the pH is adjusted with Water (and) Citric Acid.
  • part E is added.
  • UV-absorber as described in examples 1 to 4 5.00
  • Part A is prepared by incorporating all ingredients, then stirred under moderate speed and heated to 75°C.
  • Part B is prepared and heated to 75°C. At this temperature part B is poured into part A under progressive stirring speed. Then the mixture is homogenized (30sec,
  • UV-absorber as described in examples 1 to 4 5.00 Part C Diazolidinyl Urea (and) lodopropynyl Butylcarbamate 0.15
  • Part A is prepared by incorporating all ingredients, then stirred under moderate speed and heated to 75°C.
  • Part B is prepared and heated to 75°C. At this temperature, part B is poured into part A under progressive stirring speed. Below 65°C the ingredients of part D are added separately. After cooling down under moderate stirring to 55°C part C is added. The pH is then checked and adjusted with sodium hydroxide. The mixture is homogenized for 30 sec at
  • Part A is prepared by incorporating all ingredients, then stirred under moderate speed and heated to 75°C.
  • Part C is prepared and heated to 75°C.
  • Part C is poured into the part A under moderate stirring.
  • emulsification part B is added, then neutralized with a part of the triethanolamine.
  • the mixture is homogenized for 30 sec.
  • Cyclopentasiloxane (and) Dimethiconol are added. Below 35°C the pH is checked and adjusted with triethanolamine.
  • Part A and part B are heated up to 80 ⁇ C.
  • Part A is blended into part B under stirring and homogenized with an UltraTurrax at 11 000 rpm for 30 sec.
  • Part C is heated to 60 0 C and added slowly to the emulsion. After cooling down to 40°C part D is incorporated at room temperature and part E is added.
  • Part A and B are heated to 75°C. Part A is added into part B under continuous stirring and homogenized with 11000 rpm for 1 minute. After cooling down to 50 0 C part C is added under continuous stirring. After cooling further down to 30 0 C part D is added. Afterwards the pH is adjusted between 6.00 - 6.50.
  • Part A and B are heated separately to 75°C. After adding part B into part A the mixture is homogenized with Ultra Turrax for one minute at 11000 rpm. After cooling down to 50 c C part C is added. Afterwards the mixture is homogenized for one minute at 16000 rpm. At a temperature ⁇ 40 0 C part D is added. At room temperature the pH-value is adjusted with part E between 6.00 and 6.50.
  • Part A and B are heated separately up to 75 0 C, part C is heated to 60 0 C. Afterwards part B is poured into part A under stirring. The mixture is homogenized with an Ultra Turrax for 30 sec. at 11 000 rpm and part C is incorporated. After cooling down to 40 0 C part D is added. At room temperature the pH-value is adjusted with Sodium Hydroxide between 6.30 and 6.70 and part F is added.
  • Part A and B are heated separately up to 75°C, part C is heated to 60 0 C. Afterwards part B is poured into part A under stirring. The mixture is homogenized with an Ultra Turrax for 30 sec. at 11 000 rpm and part C is incorporated. After cooling down to 40 0 C part D is added. At room temperature the pH-value is adjusted with Sodium Hydroxide between 6.30 and 6.70 and part F is added.
  • Part A and part B are heated separately to 75°C.
  • Part B is added into part A under con ⁇ tinuous stirring and afterwards homogenized with Ultra Turrax for 30sec at 11000 rpm .
  • After cooling down to 60 0 C part C is added.
  • At 40 0 C part C is added and homogenized for 15sec at 11000 rpm.
  • the pH-value is adjusted with part E.
  • Example 15 UVA/UVB Daily Care Lotion, type O/W
  • Part A and B are heated separately to 75°C; part C to 60 0 C.
  • Part B is poured into part A under stirring. After one-minute of homogenization at 11000 rpm part C is added to the mixture of A/B. After cooling down to 40 0 C part D is incorporated. At room temperature the pH value is adjusted with part E between 6.3 and 7.0. Finally part F is added.
  • Example 16 UVA/UVB Daily Care Lotion, type O/W
  • Part A and part B are heated separately to 75°C.
  • Part A is poured into part B under stirring.
  • part C is added to the mixture and homogenized with an Ultra Turrax at 11000 rpm for 30 sec. After cooling down to 65°C Sodium Acrylates Copoly ⁇ mer (and) Mineral Oil (and) PPG-1 Trideceth-6
  • 0 C is added slowly to the UV absorber dispersion.
  • part F is incorporated.
  • the pH is adjusted with part G between 5.5 and 6.5.
  • Part A and part B are heated separately up to 80 0 C.
  • Part A is poured into part B while stirring and homogenized with an Ultra Turrax by 11000 rpm for 30 sec. After cooling down to 60 0 C part C is incorporated.
  • part D is added slowly under continuous stirring. The pH is adjusted with part E between 6.50 - 7.00.
  • Part A and part B are heated separately up to 80°C, part C is heated to 50°C.
  • Part B is poured into part A and homogenized with an Ultra Turrax for 1 minute at 11000 rpm. After cooling down to 50 0 C part C is added under continuous stirring. At 40 0 C part D is incor ⁇ porated and homogenized again for 10 sec. at 11000 rpm. The pH is adjusted with part E.
  • Part A and part B are heated separately up to 75°C, part C is heated to 60°C. Afterwards part B is poured into part A under stirring. The mixture is homogenized with an Ultra Turrax for 30 sec. at 11 000 rpm and part C is incorporated. After cooling down to 40 0 C part D is added. At room temperature the pH-value is adjusted with Sodium Hydroxide between 6.30 and 6.70 and part F is added.
  • Part A and part B are heated separately to 80 0 C.
  • Part A is poured into part B under con ⁇ tinuous stirring. Afterwards the mixture is homogenized with an Ultra Turrax at 11 000 rpm for 1 min. After cooling down to 60 0 C part C is incorporated. At 40 0 C part D is added and the mixture homogenized for a short time again. At 35°C part E is added and at room tempera ⁇ ture Fragrance is added. Finally the pH is adjusted with Sodium Hydroxide.
  • Example 21 UVA/UVB Sun Protection Lotion, O/W tvpe
  • Part A and part B are heated separately up to 80 0 C.
  • Part B is poured into part A under moderate stirring.
  • the mixture is homogenized with an Ultra Turrax at 11000 rpm for 1 minute. After cooling down to 70 0 C part C is added under stirring. After cooling further down to 50 0 C part D is incorporated very slowly.
  • part E is added.
  • the pH is adjusted with part F to 7.00 and part G is added.
  • Part A and part B are heated separately up to 80°C.
  • Part B is poured into part A under moderate stirring.
  • the mixture is homogenized with an Ultra Turrax at 11000 rpm for 1 minute.
  • part C is added under stirring.
  • part D is incorporated very slowly.
  • part E is added.
  • the pH is adjusted with part F to 7.00 and part G is added.
  • UV-absorber dispersion as described in examples 1 to 4 5.00 Part C Diazolidinyl Urea (and) lodopropynyl Butylcarbamate 0.15
  • Part A and part B are heated separately up to 75°C.
  • Part B is poured into part A under progressive stirring speed.
  • the ingredients of part D are added separately.
  • After cooling down to 55°C under moderate stirring part C is added.
  • At a tem ⁇ perature ⁇ 35°C the pH is checked and adjusted with Sodium Hydroxide and homogenized with an Ultra Turrax for 30 sec. at 11 000 rpm.
  • Part F is added at room temperature.
  • Part A is heated to 80°C whilst stirring.
  • Part B is added into part A and homogenized with an
  • Part A is heated separately to 80 0 C under gentle stirring.
  • Part B is added to part A and homogenized for one minute at 11000 rpm. After cooling down to 30 0 C part C is added under continuous stirring.
  • the UV absorber is dissolved in sesame oil.
  • the other components of (A) are added thereto and combined.
  • Propylparaben and methylparaben are dissolved in propylene glycol. 60 ml of water are then added, heating to 70 0 C is carried out and then carbomer 934 is emulsified therein.
  • (A) is slowly added to (B) with vigorous application of mechanical energy.
  • the volume is adjusted to 100 ml by the addition of water.
  • Example 27 Daily care cream, type CVW INCI name % w/w
  • Part A and part B are heated separately to 80 0 C.
  • Part A is poured into part B 1 whilst stirring continuously. Afterwards the mixture is homogenized with an Ultra Turrax at 11 000 rpm for 20 sec. The mixture is cooled to 60 0 C and part C is added. At a temperature below 30 0 C, part D is added and the pH value is adjusted with sodium hydroxide to between 6.5 and 7.0. Finally, fragrance is added.
  • Example 28 Sun-protection cream, type O/W
  • Part A and part B are heated separately to 75°C.
  • Part A is poured into part B whilst stirring.
  • the mixture is homogenised with an Ultra Turrax at 11 000 rpm for 15 sec.
  • the mixture is cooled to 60 0 C and part C and part D are incorporated.
  • the mixture is homogenised again for a short time (5 sec/11 000 rpm) and further cooled, with moderate stirring.
  • the pH is adjusted with sodium hydroxide solution to between 5.5 and 6.0. Finally, fragrance is added.
  • Part A and part B are heated separately to 75°C.
  • Part A is poured into part B whilst stirring.
  • the mixture is homogenised with an Ultra Turrax at 11 000 rpm for 15 sec.
  • the mixture is cooled to 60 0 C, and part C and part D are incorporated.
  • the mixture is homogenised again for a short time (5 sec/11 000 rpm).
  • the pH is adjusted with sodium hydroxide at room temperature. A solution between pH 5.50 and 6.00 is obtained. Finally, fragrance is added.
  • Part A and part B are heated separately to 75°C.
  • Part A is poured into part B whilst stirring.
  • the mixture is homogenised with an Ultra Turrax at 11 000 rpm for 15 sec.
  • part C and part D are incorporated.
  • the mixture is homogenised again for a short time (5 sec/11 000 rpm).
  • the pH is adjusted at room temperature with sodium hydroxide solution to between 5.50 and 6.00. Finally, fragrance is added.
  • Part A and part B are heated separately to 75°C.
  • Part A is poured into part B whilst stirring.
  • the mixture is homogenised with an Ultra Turrax at 11 000 rpm for 15 sec.
  • part C and part D are incorporated.
  • the mixture is homogenised again for a short time (5 sec/11 000 rpm).
  • the pH is adjusted at room temperature with sodium hydroxide. A solution between pH 5.50 and 6.00 is obtained. Finally, fragrance is added.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/EP2005/052850 2004-06-29 2005-06-20 Merocyanine derivatives Ceased WO2006003094A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2007518585A JP5078611B2 (ja) 2004-06-29 2005-06-20 メロシアニン誘導体
US11/630,489 US7772242B2 (en) 2004-06-29 2005-06-20 Merocyanine derivatives
EP05756874A EP1761237A2 (en) 2004-06-29 2005-06-20 Merocyanine derivatives
CN200580029199.XA CN101010063B (zh) 2004-06-29 2005-06-20 部花青衍生物
BRPI0512730A BRPI0512730B1 (pt) 2004-06-29 2005-06-20 preparação cosmética compreendendo derivados de merocianina, bem como dispersão de absorvedor de uv
US12/715,839 US8044058B2 (en) 2004-06-29 2010-03-02 Merocyanine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103018 2004-06-29
EP04103018.0 2004-06-29

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/630,489 A-371-Of-International US7772242B2 (en) 2004-06-29 2005-06-20 Merocyanine derivatives
US12/715,839 Division US8044058B2 (en) 2004-06-29 2010-03-02 Merocyanine derivatives
US12/715,839 Continuation US8044058B2 (en) 2004-06-29 2010-03-02 Merocyanine derivatives

Publications (2)

Publication Number Publication Date
WO2006003094A2 true WO2006003094A2 (en) 2006-01-12
WO2006003094A3 WO2006003094A3 (en) 2006-07-13

Family

ID=34854709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/052850 Ceased WO2006003094A2 (en) 2004-06-29 2005-06-20 Merocyanine derivatives

Country Status (10)

Country Link
US (2) US7772242B2 (enExample)
EP (1) EP1761237A2 (enExample)
JP (1) JP5078611B2 (enExample)
KR (1) KR20070026590A (enExample)
CN (1) CN101010063B (enExample)
AR (1) AR055685A1 (enExample)
BR (1) BRPI0512730B1 (enExample)
GB (1) GB2416351A (enExample)
TW (1) TW200613001A (enExample)
WO (1) WO2006003094A2 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014848A3 (en) * 2005-07-29 2007-05-03 Ciba Sc Holding Ag Stabilization of body-care and household products against degradation by uv radiation using merocyanine derivatives
WO2007068709A1 (de) * 2005-12-13 2007-06-21 Beiersdorf Ag Merocyaninhaltige sonnenschutzmittel mit hoher uv-a-balance
WO2007068707A3 (de) * 2005-12-13 2007-09-07 Beiersdorf Ag Sonnenschutzmittel mit merocyaninen und triazinen
EP1864647A1 (de) * 2006-06-09 2007-12-12 Beiersdorf AG Acyclische Merocyanine in kosmetischen Zubereitungen
EP1864648A1 (de) * 2006-06-09 2007-12-12 Beiersdorf AG Kosmetische Zubereitung mit acyclischem Merocyanin
WO2008080645A1 (en) 2006-10-13 2008-07-10 Ciba Holding Inc. Merocyanine derivatives
WO2008090066A3 (en) * 2007-01-25 2008-09-12 Ciba Holding Inc Stabilization of uv-sensitive active ingredients
JP2008542459A (ja) * 2005-05-27 2008-11-27 ロレアル メロシアニンスルホン誘導体を使用するジベンゾイルメタン誘導体の光安定化方法;前記組み合わせを含む光保護性化粧品組成物
EP2193784A1 (fr) 2008-12-08 2010-06-09 L'oreal Compositions cosmetiques comprenant un derive ester de 2-pyrrolidinone 4- carboxy et un filtre lipophile triazine ; utilisation dudit derive comme solvant d'un filtre lipophile triazine
EP2441754A1 (en) * 2010-10-13 2012-04-18 Deutsches Krebsforschungszentrum A new dimedon derivative and a method for the purification of PNA and peptide oligomers
US8318980B2 (en) 2007-09-18 2012-11-27 Fujifilm Manufacturing Europe B.V. UV absorbing compounds
CN101277674B (zh) * 2005-07-29 2013-01-16 西巴特殊化学制品控股公司 使用部花青衍生物使身体护理产品和家用产品稳定化防止uv辐射引起的降解
KR20170117754A (ko) * 2016-04-14 2017-10-24 고려대학교 산학협력단 비-후각 조직 중 후각 수용체에 대한 효능제 화합물 및 그 제조방법

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2416351A (en) * 2004-06-29 2006-01-25 Ciba Sc Holding Ag Use of myocyanine derivatives for the protection of human hair and skin from UV radiation
GB2433499A (en) 2005-12-20 2007-06-27 Ciba Sc Holding Ag Merocyanine derivatives useful as UV absorbing agents
JP2010111823A (ja) * 2008-11-10 2010-05-20 Fujifilm Corp 紫外線吸収組成物、それを用いた化粧品、医薬製剤及び、紫外線の遮断方法
BR112012003915B1 (pt) * 2009-08-25 2017-07-25 L'oreal Cosmetic composition for keratin fibers
US20120269749A1 (en) * 2009-11-05 2012-10-25 Herve Richard Cosmetic compositions comprising an ester derived from 4-carboxy-2-pyrrolidinone and a merocyanin screening agent; use of said derivative as a solvent for a merocyanin screening agent
BR112012023232B1 (pt) * 2010-03-15 2021-03-23 L'oreal Composição, processo para melhorar a estabilidade química em relação à radiação uv e compostos de merocianina
FR2957250B1 (fr) * 2010-03-15 2012-03-23 Oreal Composition contenant un filtre dibenzoylmethane et un filtre uv merocyanine hydrophile ou hydrosoluble ; procede de photostabilisation du filtre dibenzoylmethane
US8476251B2 (en) 2010-07-29 2013-07-02 Conopco, Inc. Skin care compositions comprising substituted diamines
US8293218B2 (en) 2010-07-29 2012-10-23 Conopco, Inc. Skin care compositions comprising substituted monoamines
WO2013010590A1 (en) * 2011-07-21 2013-01-24 L'oreal Cosmetic and/or dermatological composition containing a merocyanine derivative comprising specific polar groups consisting of hydroxyl- and ether-functionalities
FR3001137B1 (fr) * 2013-01-21 2015-02-27 Oreal Emulsion eau-dans-huile cosmetique ou dermatologique comprenant une merocyanine et au moins un polymere emulsionnant du type ester d'acide gras et de glycol polyoxyalkylene
JP6426355B2 (ja) * 2014-03-11 2018-11-21 株式会社アリミノ 毛髪および肌用化粧料
KR102594786B1 (ko) * 2019-07-09 2023-10-26 후지필름 가부시키가이샤 점착제 시트, 적층체, 표시 장치, 유기 일렉트로 루미네선스 표시 장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE947185C (de) 1953-04-24 1956-08-09 Agfa Ag Fuer Photofabrikation Verfahren zur Herstellung von Cyaninfarbstoffen
US4457911A (en) * 1981-01-28 1984-07-03 Van Dyk & Company Inc. Dialkyl malonates as organic sunscreen adjuvants
US5380700A (en) 1991-03-26 1995-01-10 Kumiai Chemical Industries Co., Ltd. Pyridine derivatives, herbicidal composition containing the same, and method for killing weeds
JPH05331163A (ja) * 1991-03-26 1993-12-14 Kumiai Chem Ind Co Ltd ピリジン誘導体及び除草剤
JPH08239509A (ja) * 1995-03-06 1996-09-17 Fuji Photo Film Co Ltd ポリマーフィルム
JPH11302273A (ja) * 1997-10-28 1999-11-02 Chemiprokasei Kaisha Ltd アミノメチレンピラン誘導体、その製造方法および用途
FR2815961B1 (fr) 2000-10-26 2008-11-28 Centre Nat Rech Scient Nouveaux intermediaires utiles pour la synthese de retinoides
US6783754B2 (en) 2001-06-11 2004-08-31 Roy J. Mankovitz Plant-based non-toxic sunscreen products
ES2269978T3 (es) * 2002-02-12 2007-04-01 Dsm Ip Assets B.V. Composiciones para filtros solares asi como dihidropiridinas y dihidropiranos.
DK1549283T3 (da) 2002-07-10 2013-01-02 Basf Se Merocyanine derivatives for cosmetic use
DE10240863A1 (de) * 2002-09-04 2004-03-18 Basf Ag Verwendung von 2-(4-Diethylamino-2-hydroxybenzoyl)-benzoesäure-n-hexylester in kosmetischen oder dermatologischen Zubereitungen zur Behandlung von Haaren
WO2004075871A1 (en) * 2003-02-26 2004-09-10 Fuji Photo Film B.V. Cosmetic uv-screen compositions and aminobutadiene-based uv-absorbing complexes therefor
KR20060040700A (ko) * 2003-07-22 2006-05-10 시바 스페셜티 케미칼스 홀딩 인크. O-배위된 금속 킬레이트 및 저장 용량이 큰 광기록매체에서의 이의 용도
JP2007514709A (ja) * 2003-12-17 2007-06-07 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 化粧品用メロシアニン誘導体
US7897779B2 (en) * 2004-02-13 2011-03-01 Dsm Ip Assets B.V. Ionic UV-A sunscreens and compositions containing them
GB2416351A (en) * 2004-06-29 2006-01-25 Ciba Sc Holding Ag Use of myocyanine derivatives for the protection of human hair and skin from UV radiation

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542459A (ja) * 2005-05-27 2008-11-27 ロレアル メロシアニンスルホン誘導体を使用するジベンゾイルメタン誘導体の光安定化方法;前記組み合わせを含む光保護性化粧品組成物
US8829192B2 (en) 2005-07-29 2014-09-09 Basf Se Stabilization of body-care and household products against degradation by uv radiation using merocyanine derivatives
EP2272490A3 (en) * 2005-07-29 2011-09-21 Basf Se Stabilization of body-care and household products against degradation by UV radiation using merocyanine derivatives
CN101277674B (zh) * 2005-07-29 2013-01-16 西巴特殊化学制品控股公司 使用部花青衍生物使身体护理产品和家用产品稳定化防止uv辐射引起的降解
JP2009503172A (ja) * 2005-07-29 2009-01-29 チバ ホールディング インコーポレーテッド メロシアニン誘導体を使用することによる紫外線による劣化に対するボディケア及び家庭用品の安定化
WO2007014848A3 (en) * 2005-07-29 2007-05-03 Ciba Sc Holding Ag Stabilization of body-care and household products against degradation by uv radiation using merocyanine derivatives
WO2007068709A1 (de) * 2005-12-13 2007-06-21 Beiersdorf Ag Merocyaninhaltige sonnenschutzmittel mit hoher uv-a-balance
WO2007068707A3 (de) * 2005-12-13 2007-09-07 Beiersdorf Ag Sonnenschutzmittel mit merocyaninen und triazinen
EP1864647A1 (de) * 2006-06-09 2007-12-12 Beiersdorf AG Acyclische Merocyanine in kosmetischen Zubereitungen
EP1864648A1 (de) * 2006-06-09 2007-12-12 Beiersdorf AG Kosmetische Zubereitung mit acyclischem Merocyanin
US9068080B2 (en) * 2006-10-13 2015-06-30 Basf Se Merocyanine derivatives
JP2010505903A (ja) * 2006-10-13 2010-02-25 チバ ホールディング インコーポレーテッド メロシアニン誘導体
US20100035839A1 (en) * 2006-10-13 2010-02-11 Ciba Corporation Merocyanine derivatives
WO2008080645A1 (en) 2006-10-13 2008-07-10 Ciba Holding Inc. Merocyanine derivatives
US8535648B2 (en) 2007-01-25 2013-09-17 Basf Se Stabilization of UV-sensitive active ingredients
CN101711151B (zh) * 2007-01-25 2013-12-18 西巴控股公司 Uv-敏感活性成分的稳定作用
JP2010516725A (ja) * 2007-01-25 2010-05-20 チバ ホールディング インコーポレーテッド 紫外線感受性有効成分の安定化
KR101468484B1 (ko) * 2007-01-25 2014-12-04 시바 홀딩 인코포레이티드 유기 uv 민감성 활성 성분의 안정화
WO2008090066A3 (en) * 2007-01-25 2008-09-12 Ciba Holding Inc Stabilization of uv-sensitive active ingredients
US8318980B2 (en) 2007-09-18 2012-11-27 Fujifilm Manufacturing Europe B.V. UV absorbing compounds
EP2193784A1 (fr) 2008-12-08 2010-06-09 L'oreal Compositions cosmetiques comprenant un derive ester de 2-pyrrolidinone 4- carboxy et un filtre lipophile triazine ; utilisation dudit derive comme solvant d'un filtre lipophile triazine
WO2012048877A1 (en) * 2010-10-13 2012-04-19 Deutsches Krebsforschungszentrum A new dimedon derivative and a method for the purification of pna and peptide oligomers
EP2441754A1 (en) * 2010-10-13 2012-04-18 Deutsches Krebsforschungszentrum A new dimedon derivative and a method for the purification of PNA and peptide oligomers
KR20170117754A (ko) * 2016-04-14 2017-10-24 고려대학교 산학협력단 비-후각 조직 중 후각 수용체에 대한 효능제 화합물 및 그 제조방법
KR102613001B1 (ko) * 2016-04-14 2023-12-12 고려대학교 세종산학협력단 비-후각 조직 중 후각 수용체에 대한 효능제 화합물 및 그 제조방법

Also Published As

Publication number Publication date
JP2008504343A (ja) 2008-02-14
US20090010860A1 (en) 2009-01-08
CN101010063B (zh) 2016-12-07
US20100209466A1 (en) 2010-08-19
JP5078611B2 (ja) 2012-11-21
GB0512335D0 (en) 2005-07-27
BRPI0512730A2 (pt) 2011-10-11
GB2416351A (en) 2006-01-25
CN101010063A (zh) 2007-08-01
US8044058B2 (en) 2011-10-25
AR055685A1 (es) 2007-09-05
US7772242B2 (en) 2010-08-10
BRPI0512730B1 (pt) 2016-06-14
WO2006003094A3 (en) 2006-07-13
EP1761237A2 (en) 2007-03-14
TW200613001A (en) 2006-05-01
KR20070026590A (ko) 2007-03-08

Similar Documents

Publication Publication Date Title
US8044058B2 (en) Merocyanine derivatives
EP1701695B1 (en) Merocyanine derivatives for cosmetic use
EP1963257B1 (en) Merocyanine derivatives
JP4154719B2 (ja) 化粧品用途のためのメロシアニン誘導体
JP4566907B2 (ja) アミノ置換ヒドロキシフェニルベンゾフェノン誘導体
EP2016059B1 (en) Triazine derivatives
JP4344241B2 (ja) トリアジン誘導体、およびサンスクリーンとしてのその使用
EP2125961B1 (en) Siloxane-merocyanine dyes
EP1981895B1 (en) Hydroxybenzophenone derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005756874

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067026302

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11630489

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007518585

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 4773/CHENP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200580029199.X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020067026302

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005756874

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512730

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20061228